Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia

MR Lidonnici, Y Paleari, F Tiboni, G Mandelli, C Rossi, M Vezzoli, Annamaria Aprile, CW Lederer, A Ambrosi, F Chanut, F Sanvito, A Calabria, Valentina Poletti, F Mavilio, E Montini, L Naldini, Patrizia Cristofori, G Ferrari

Research output: Contribution to journalArticle

Abstract

Gene therapy clinical trials require rigorous non-clinical studies in the most relevant models to assess the benefit-to-risk ratio. To support the clinical development of gene therapy for β-thalassemia, we performed in vitro and in vivo studies for prediction of safety. First we developed newly GLOBE-derived vectors that were tested for their transcriptional activity and potential interference with the expression of surrounding genes. Because these vectors did not show significant advantages, GLOBE lentiviral vector (LV) was elected for further safety characterization. To support the use of hematopoietic stem cells (HSCs) transduced by GLOBE LV for the treatment of β-thalassemia, we conducted toxicology, tumorigenicity, and biodistribution studies in compliance with the OECD Principles of Good Laboratory Practice. We demonstrated a lack of toxicity and tumorigenic potential associated with GLOBE LV-transduced cells. Vector integration site (IS) studies demonstrated that both murine and human transduced HSCs retain self-renewal capacity and generate new blood cell progeny in the absence of clonal dominance. Moreover, IS analysis showed an absence of enrichment in cancer-related genes, and the genes targeted by GLOBE LV in human HSCs are well known sites of integration, as seen in other lentiviral gene therapy trials, and have not been associated with clonal expansion. Taken together, these integrated studies provide safety data supporting the clinical application of GLOBE-mediated gene therapy for β-thalassemia. © 2018 The Author(s)
Original languageEnglish
Pages (from-to)9-28
Number of pages20
JournalMolecular Therapy - Methods and Clinical Development
Volume11
DOIs
Publication statusPublished - 2018

Fingerprint

Lentivirus
Thalassemia
Genetic Therapy
Hematopoietic Stem Cells
Safety
Neoplasm Genes
Toxicology
Blood Cells
Odds Ratio
Clinical Trials
Gene Expression
Genes
Therapeutics

Cite this

Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia. / Lidonnici, MR; Paleari, Y; Tiboni, F; Mandelli, G; Rossi, C; Vezzoli, M; Aprile, Annamaria; Lederer, CW; Ambrosi, A; Chanut, F; Sanvito, F; Calabria, A; Poletti, Valentina; Mavilio, F; Montini, E; Naldini, L; Cristofori, Patrizia; Ferrari, G.

In: Molecular Therapy - Methods and Clinical Development, Vol. 11, 2018, p. 9-28.

Research output: Contribution to journalArticle

Lidonnici, MR ; Paleari, Y ; Tiboni, F ; Mandelli, G ; Rossi, C ; Vezzoli, M ; Aprile, Annamaria ; Lederer, CW ; Ambrosi, A ; Chanut, F ; Sanvito, F ; Calabria, A ; Poletti, Valentina ; Mavilio, F ; Montini, E ; Naldini, L ; Cristofori, Patrizia ; Ferrari, G. / Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia. In: Molecular Therapy - Methods and Clinical Development. 2018 ; Vol. 11. pp. 9-28.
@article{48748e8f8c5f49c8a4e6f31d711ffa8c,
title = "Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia",
abstract = "Gene therapy clinical trials require rigorous non-clinical studies in the most relevant models to assess the benefit-to-risk ratio. To support the clinical development of gene therapy for β-thalassemia, we performed in vitro and in vivo studies for prediction of safety. First we developed newly GLOBE-derived vectors that were tested for their transcriptional activity and potential interference with the expression of surrounding genes. Because these vectors did not show significant advantages, GLOBE lentiviral vector (LV) was elected for further safety characterization. To support the use of hematopoietic stem cells (HSCs) transduced by GLOBE LV for the treatment of β-thalassemia, we conducted toxicology, tumorigenicity, and biodistribution studies in compliance with the OECD Principles of Good Laboratory Practice. We demonstrated a lack of toxicity and tumorigenic potential associated with GLOBE LV-transduced cells. Vector integration site (IS) studies demonstrated that both murine and human transduced HSCs retain self-renewal capacity and generate new blood cell progeny in the absence of clonal dominance. Moreover, IS analysis showed an absence of enrichment in cancer-related genes, and the genes targeted by GLOBE LV in human HSCs are well known sites of integration, as seen in other lentiviral gene therapy trials, and have not been associated with clonal expansion. Taken together, these integrated studies provide safety data supporting the clinical application of GLOBE-mediated gene therapy for β-thalassemia. {\circledC} 2018 The Author(s)",
author = "MR Lidonnici and Y Paleari and F Tiboni and G Mandelli and C Rossi and M Vezzoli and Annamaria Aprile and CW Lederer and A Ambrosi and F Chanut and F Sanvito and A Calabria and Valentina Poletti and F Mavilio and E Montini and L Naldini and Patrizia Cristofori and G Ferrari",
year = "2018",
doi = "10.1016/j.omtm.2018.09.001",
language = "English",
volume = "11",
pages = "9--28",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia

AU - Lidonnici, MR

AU - Paleari, Y

AU - Tiboni, F

AU - Mandelli, G

AU - Rossi, C

AU - Vezzoli, M

AU - Aprile, Annamaria

AU - Lederer, CW

AU - Ambrosi, A

AU - Chanut, F

AU - Sanvito, F

AU - Calabria, A

AU - Poletti, Valentina

AU - Mavilio, F

AU - Montini, E

AU - Naldini, L

AU - Cristofori, Patrizia

AU - Ferrari, G

PY - 2018

Y1 - 2018

N2 - Gene therapy clinical trials require rigorous non-clinical studies in the most relevant models to assess the benefit-to-risk ratio. To support the clinical development of gene therapy for β-thalassemia, we performed in vitro and in vivo studies for prediction of safety. First we developed newly GLOBE-derived vectors that were tested for their transcriptional activity and potential interference with the expression of surrounding genes. Because these vectors did not show significant advantages, GLOBE lentiviral vector (LV) was elected for further safety characterization. To support the use of hematopoietic stem cells (HSCs) transduced by GLOBE LV for the treatment of β-thalassemia, we conducted toxicology, tumorigenicity, and biodistribution studies in compliance with the OECD Principles of Good Laboratory Practice. We demonstrated a lack of toxicity and tumorigenic potential associated with GLOBE LV-transduced cells. Vector integration site (IS) studies demonstrated that both murine and human transduced HSCs retain self-renewal capacity and generate new blood cell progeny in the absence of clonal dominance. Moreover, IS analysis showed an absence of enrichment in cancer-related genes, and the genes targeted by GLOBE LV in human HSCs are well known sites of integration, as seen in other lentiviral gene therapy trials, and have not been associated with clonal expansion. Taken together, these integrated studies provide safety data supporting the clinical application of GLOBE-mediated gene therapy for β-thalassemia. © 2018 The Author(s)

AB - Gene therapy clinical trials require rigorous non-clinical studies in the most relevant models to assess the benefit-to-risk ratio. To support the clinical development of gene therapy for β-thalassemia, we performed in vitro and in vivo studies for prediction of safety. First we developed newly GLOBE-derived vectors that were tested for their transcriptional activity and potential interference with the expression of surrounding genes. Because these vectors did not show significant advantages, GLOBE lentiviral vector (LV) was elected for further safety characterization. To support the use of hematopoietic stem cells (HSCs) transduced by GLOBE LV for the treatment of β-thalassemia, we conducted toxicology, tumorigenicity, and biodistribution studies in compliance with the OECD Principles of Good Laboratory Practice. We demonstrated a lack of toxicity and tumorigenic potential associated with GLOBE LV-transduced cells. Vector integration site (IS) studies demonstrated that both murine and human transduced HSCs retain self-renewal capacity and generate new blood cell progeny in the absence of clonal dominance. Moreover, IS analysis showed an absence of enrichment in cancer-related genes, and the genes targeted by GLOBE LV in human HSCs are well known sites of integration, as seen in other lentiviral gene therapy trials, and have not been associated with clonal expansion. Taken together, these integrated studies provide safety data supporting the clinical application of GLOBE-mediated gene therapy for β-thalassemia. © 2018 The Author(s)

U2 - 10.1016/j.omtm.2018.09.001

DO - 10.1016/j.omtm.2018.09.001

M3 - Article

VL - 11

SP - 9

EP - 28

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -